輝瑞和風投公司Flagship Pioneering將投資1億美元用於新藥研發
格隆匯7月18日丨輝瑞和風險投資公司Flagship Pioneering週二同意投資1億美元用於研究和開發10種新的潛在藥物,這些藥物將針對治療選擇很少或沒有治療選擇的疾病。輝瑞將獲得Pioneering的研究平台和臨牀前研究資源,為每種選定藥物的開發提供資金,並有權選擇收購這些藥物。在合作中發現和開發的任何實驗性治療藥物成功上市和銷售後,Flagship Pioneering支持的公司可獲得高達7億美元的里程碑和特許權使用費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.